AstraZeneca Notches Another Indication for Imfinzi, Pushing PD-L1 Blocker Into Stomach Cancer Leave a Comment / By Leonardo Arias / 26/11/2025 Imfinzi is the first immunotherapy approved for perioperative use to treat gastric and gastroesophageal junction cancers.
